Sells genetic diagnostic tests for cancer patients, people seeking prenatal or hereditary screening, and transplant recipients.
10-K for FY2025, filed Feb 27, 2026We focus on applying our technology to three main areas of healthcare – oncology, women’s health, and organ health. Since 2009, we have…View ↗
Our technology is compatible with standard equipment used globally and a range of next generation sequencing, or NGS, platforms, and we…View ↗
OncologyView ↗
Women’s HealthView ↗
Most money comes from genetic tests for patients, clinics and insurers. Natera generally bills when test results are delivered; laboratory partners may pay a fixed amount per test or a share of their collections.
10-K for FY2025, filed Feb 27, 2026We generate revenues from the sale of our tests, primarily from the sale of our Signatera, Panorama and HCS tests. Our two primary…View ↗
In cases where we sell our tests through our laboratory partners, the majority of our laboratory partners bill the patient, clinic or…View ↗
Product revenues are derived by performing genetic testing services and the Company’s performance obligation is complete when test results…View ↗
The Company generally bills an insurance carrier, a laboratory partner or a patient upon delivery of test results. The Company also bills…View ↗
10-K for FY2025, filed Feb 27, 2026
FY2025 revenue by product or service ↗$2.3B
10-K for FY2025, filed Feb 27, 2026
$2.3B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Feb 27, 2026 |
100%
FY2022: 97%
|
Product, FY2025
$2.3B Sources
|
Sold outright |
|
Licensing and other
Usage-based
|
0.5%
FY2022: 2.8%
|
Licensing and other, FY2025
$10.3M Sources
|
Usage-based |
Customers include independent and reference laboratories, medical centers, physician practices, research laboratories and pharmaceutical companies. Tests are sold through Natera’s direct sales force and laboratory partners; some partners bill clinics, patients and insurers themselves.
10-K for FY2025, filed Feb 27, 2026We process tests in our laboratories certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, primarily in Austin…View ↗
We generate revenues from the sale of our tests, primarily from the sale of our Signatera, Panorama and HCS tests. Our two primary…View ↗
In cases where we sell our tests through our laboratory partners, the majority of our laboratory partners bill the patient, clinic or…View ↗
Not on paper. It lost $208.2M in FY2025, but brought in more cash than it spent: $109.1M of free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$59.9MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Aug 6, 2026
Generated total revenues of $752.8 million in the second quarter of 2026, compared to $546.6 million in the second quarter of 2025, an…View ↗
Growing. Revenue grew 3.7x in 4 years, from $625.5M in FY2021 to $2.3B in FY2025, about 39% a year.
Broader oncology focus
The older report described oncology as an area where the company was proving its technology and commercializing a personalized blood test. The latest report describes a broader oncology offering, including tests for monitoring cancer and treatment response, genomic profiling and hereditary cancer screening.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 27, 2026Our initial focus was in the women’s health space, in which we develop and commercialize non- or minimally- invasive tests to evaluate risk…View ↗
We focus on applying our technology to three main areas of healthcare – oncology, women’s health, and organ health. Since 2009, we have…View ↗
Signatera is our personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in…View ↗
Altera is our tissue based comprehensive genomic profiling test that provides insight into genomic alterations and biomarkers found in a…View ↗
Empower, our hereditary cancer screening test, offers five panel options across 12 common hereditary cancer types, and customizable panels…View ↗
Competes with BGI, BillionToOne, Fulgent Genetics, Illumina, Labcorp, Myriad Genetics, Quest Diagnostics, Revvity, Caris Life Sciences, Exact Sciences, Guardant Health, Personalis, Tempus Labs, and CareDx
10-K for FY2025, filed Feb 27, 2026Our competitors in the NIPT space include BGI; BillionToOne Inc.; Fulgent Genetics; Illumina, through its subsidiary Verinata; Laboratory…View ↗
Loading...